Surge Biswas

Allow me to introduce you to the phenomenon that is Surge Biswas. This guy’s the real deal in biotech and AI, no cap. He’s the co-founder and CEO of Nabla Bio, a Boston-based startup that’s crushing it in antibody design using AI. They’re basically trying to hack the hardest diseases out there with crazy technology.

Surge’s process is pretty nuts. He did his PhD at Harvard in George Church’s lab, yeah, that George Church, one of the OGs in biotech. While he was there, he basically pioneered protein language modeling, which is like applying natural language processing to amino acids. Think about it, using AI to actually understand protein structures and then design new ones. That’s some advanced shit. He developed the core tech for Nabla during his grad studies, focusing on using machine learning to get a whole view of antibodies. It’s like he took NLP and mashed it up with biology, which is kinda genius if you think about it.

He jumped into the startup world in 2020 with Nabla Bio, and the vision was clear: use AI and tons of experiments to create antibodies for diseases that are super tough to crack. And he’s not just talking, Nabla’s raised over $11 million from heavy hitters like Y Combinator, Khosla Ventures, and others. That’s a solid vote of confidence that he’s onto something big.

Before Nabla, Surge was tinkering in the lab at Phil Wigge’s place, just grinding in the science trenches. But his real passion? Building stuff that actually changes the game. His background shows he’s all about pushing the boundaries of what’s possible with tech and biology. And his partnership with his wife, Frances Anastassacos, who’s also a co-founder, just shows he’s got that team vibe, building something meaningful with people he trusts.

Honestly, Surge’s story is about relentless curiosity, a total no BS attitude, and a drive to solve real problems using crazy tech. He’s the kind of founder who’s not just in it for the hype, he’s genuinely trying to make a difference, one antibody at a time. That’s why he’s important. He’s not just another startup guy; he’s the future of biotech and AI combined.